ATE273320T1 - Fusogene liposomen - Google Patents

Fusogene liposomen

Info

Publication number
ATE273320T1
ATE273320T1 AT97915236T AT97915236T ATE273320T1 AT E273320 T1 ATE273320 T1 AT E273320T1 AT 97915236 T AT97915236 T AT 97915236T AT 97915236 T AT97915236 T AT 97915236T AT E273320 T1 ATE273320 T1 AT E273320T1
Authority
AT
Austria
Prior art keywords
fusogenic liposomes
liposomes
virosomal
virosomes
liposomal
Prior art date
Application number
AT97915236T
Other languages
English (en)
Inventor
Pieter R Cullis
Lewis S L Choi
Myrna Monck
Austin Bailey
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Application granted granted Critical
Publication of ATE273320T1 publication Critical patent/ATE273320T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
AT97915236T 1996-04-11 1997-04-10 Fusogene liposomen ATE273320T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1529296P 1996-04-11 1996-04-11
PCT/CA1997/000245 WO1997038010A2 (en) 1996-04-11 1997-04-10 Fusogenic liposomes

Publications (1)

Publication Number Publication Date
ATE273320T1 true ATE273320T1 (de) 2004-08-15

Family

ID=21770580

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97915236T ATE273320T1 (de) 1996-04-11 1997-04-10 Fusogene liposomen

Country Status (7)

Country Link
US (2) US6417326B1 (de)
EP (1) EP0910576B1 (de)
AT (1) ATE273320T1 (de)
AU (1) AU2284697A (de)
CA (1) CA2252055C (de)
DE (1) DE69730218D1 (de)
WO (1) WO1997038010A2 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113347A1 (en) * 1991-05-08 2003-06-19 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
US7422902B1 (en) * 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) * 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
DE69730218D1 (de) 1996-04-11 2004-09-16 Univ British Columbia Fusogene liposomen
WO1998051278A2 (en) * 1997-05-14 1998-11-19 Inex Pharmaceuticals Corporation High efficiency encapsulation of charged therapeutic agents in lipid vesicles
GB9721901D0 (en) * 1997-10-16 1997-12-17 Univ Manchester Particles
WO1999030686A1 (en) * 1997-12-12 1999-06-24 Inex Pharmaceuticals Corp. Cationic drugs encapsulated in anionic liposomes
IL126681A0 (en) * 1998-10-21 1999-08-17 Opperbas Holding Bv Treatment of trauma-related conditions
US7094423B1 (en) * 1999-07-15 2006-08-22 Inex Pharmaceuticals Corp. Methods for preparation of lipid-encapsulated therapeutic agents
US20050249794A1 (en) * 1999-08-27 2005-11-10 Semple Sean C Compositions for stimulating cytokine secretion and inducing an immune response
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
WO2001080900A2 (en) * 2000-04-20 2001-11-01 The University Of British Columbia Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane
GB0100196D0 (en) * 2001-01-04 2001-02-14 Anmat Technology Ltd Peptides
EP1852126B1 (de) * 2001-03-27 2013-05-15 Oncothyreon Inc. Impfstoff zur Modulation zwischen T1 und T2 Immunantworten
CA2441809C (en) 2001-03-27 2014-07-22 Biomira, Inc. Liposomal vaccines comprising dilipopeptides for modulating t1 and t2 immune responses
US20030077829A1 (en) * 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
US20030125292A1 (en) * 2001-11-07 2003-07-03 Sean Semple Mucoscal vaccine and methods for using the same
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
US7056529B2 (en) * 2002-05-14 2006-06-06 University Of Louisville Research Foundation, Inc. Direct cellular energy delivery system
US20060193905A1 (en) * 2002-05-14 2006-08-31 University Of Louisville Research Foundation, Inc. Direct cellular energy delivery system
MXPA05003884A (es) 2002-10-16 2005-10-05 Euro Celtique Sa Anticuerpos que enlazan polipeptidos ca 125/0772p a celulas asociadas y metodos de uso de los mismos.
US20070112176A1 (en) * 2003-04-04 2007-05-17 Daiichi Pharmaceutical Co., Ltd. Lipid membrane structure containing anti-mt-mmp monoclonal antibody
EP1617808A4 (de) * 2003-04-25 2011-11-02 Penn State Res Found Verfahren und system für die systemische abgabe von wachstumshemmenden von lipiden stammenden bioaktiven verbindungen
TWI329130B (en) * 2003-06-19 2010-08-21 Bestewil Holding Bv Functionally reconstituted viral membranes containing adjuvant
JP4628955B2 (ja) * 2003-10-01 2011-02-09 独立行政法人科学技術振興機構 核移行能を有するポリアルギニン修飾リポソーム
WO2005034979A2 (en) * 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
US20050214356A1 (en) * 2004-03-24 2005-09-29 Joyce Timothy H Self assembling activation agents targeted using active drug release
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
UA86063C2 (ru) 2004-05-03 2009-03-25 Хермес Біосайенсез, Інк. Липосомы для снабжения лекарств
JP4692983B2 (ja) * 2004-07-12 2011-06-01 独立行政法人科学技術振興機構 リポソーム封入物質がエンドソームから脱出可能なリポソーム
US20080051323A1 (en) * 2004-08-21 2008-02-28 Kosak Kenneth M Chloroquine drug compositions and methods for their synthesis
US20060045910A1 (en) * 2004-09-02 2006-03-02 Ehringer William D Preserved fusogenic vesicles
US20060134189A1 (en) * 2004-11-17 2006-06-22 Protiva Biotherapeutics, Inc siRNA silencing of apolipoprotein B
AU2006274651B2 (en) 2005-06-28 2012-09-27 Oncothyreon Inc. Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
CN101346393B (zh) 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
WO2008105178A1 (ja) * 2007-02-28 2008-09-04 National University Corporation Hokkaido University リポソーム用生体成分抵抗性増強剤及びこれにより修飾されたリポソーム
KR100890317B1 (ko) * 2008-05-08 2009-03-26 고려대학교 산학협력단 플라티늄 항암제 조성물 및 제제
EP2123258A1 (de) * 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomen zur Arzneimittelverabreichung
CA2730737A1 (en) * 2008-07-15 2010-01-21 Novartis Ag Immunogenic amphipathic peptide compositions
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
WO2011000108A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein b
ME03091B (de) 2009-12-01 2019-01-20 Translate Bio Inc Ausgabe von mrna zur vermehrung von proteinen und enzymen bei humangenetischen erkrankungen
SMT202200311T1 (it) 2010-08-31 2022-09-14 Glaxosmithkline Biologicals Sa Liposomi pegilati per somministrare rna codificante un immunogene
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
CA2825972A1 (en) 2011-02-24 2012-08-30 Oncothyreon Inc. Muc1 based glycolipopeptide vaccine with adjuvant
US9532950B2 (en) * 2011-03-14 2017-01-03 National University Corporation Hokkaido University Vector for pulmonary delivery, inducing agent, and uses
CA2833269C (en) * 2011-04-15 2020-04-14 Molecular Transfer, Inc. Agents for improved delivery of nucleic acids to eukaryotic cells
PT2717893T (pt) 2011-06-08 2019-08-20 Translate Bio Inc Composições de nanopartículas lipídicas e métodos para transferência de arnm
KR20140097215A (ko) 2011-10-31 2014-08-06 말린크로트 엘엘씨 암 치료를 위한 조합 리포좀 조성물
US9080144B2 (en) * 2012-05-10 2015-07-14 Muhammad Naveed Yousaf Compositions and methods for promoting liposomal and cellular adhesion
US20150267192A1 (en) 2012-06-08 2015-09-24 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
EP2912045A4 (de) 2012-10-29 2016-07-13 Molecular Transfer Inc Polykationische methylphospholipide zur verbesserten freisetzung von nukleinsäuren in eukaryotischen zellen
US8999925B2 (en) * 2013-02-26 2015-04-07 The Administrators Of The Tulane Educational Fund Arenavirus inhibiting peptides and uses therefor
KR20150128687A (ko) 2013-03-14 2015-11-18 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna의 정제 방법
CA2904151C (en) 2013-03-14 2023-09-12 Shire Human Genetic Therapies, Inc. Cftr mrna compositions and related methods and uses
US10017460B2 (en) 2013-06-12 2018-07-10 Organolinx Corp. Compounds for promoting liposomal and cellular adhesion and compositions and methods of use thereof
EA201992208A1 (ru) 2013-10-22 2020-07-31 Транслейт Био, Инк. ЛЕЧЕНИЕ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
BR112016009014B1 (pt) 2013-10-22 2024-02-06 Translate Bio, Inc USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE
EP2910239A1 (de) * 2014-02-20 2015-08-26 Universitat Autònoma De Barcelona Neue Zusammensetzungen aus lipidbeschichteten Bakteriophagen
KR102739894B1 (ko) 2014-04-25 2024-12-05 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna 의 정제 방법
US9968683B2 (en) 2014-12-17 2018-05-15 Organolinx Corp. Method for conjugating molecules
MX382522B (es) 2015-10-16 2025-03-13 Ipsen Biopharm Ltd Composiciones farmaceuticas estabilizantes de camptotecina.
CN105801668B (zh) * 2016-04-01 2020-08-07 天津大学 一种寡聚精氨酸修饰的磷脂与其组装的纳米粒及制备方法和应用
EP3538546B1 (de) 2016-11-14 2025-01-08 Novartis AG Zusammensetzungen, methoden und therapeutische verwendungen des fusogenen proteins minion
MX2019010155A (es) 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
WO2018213476A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
US11389405B2 (en) * 2017-09-18 2022-07-19 North Carolina State University Artificial beta cells and methods of use thereof
US10849924B2 (en) 2017-09-26 2020-12-01 New York Medical College Compositions and methods for restoring endothelial glycocalyx
WO2020041793A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
MX2021005969A (es) 2018-11-21 2021-09-14 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado.
JP2025523368A (ja) 2022-05-30 2025-07-23 シャンハイ サーコード バイオメッド カンパニー，リミティド 合成環状ｒｎａ組成物及びその使用方法
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
WO2025101976A1 (en) * 2023-11-09 2025-05-15 Mercury Bio, Inc. Chimeric yeast extracellular vesicles for the enhanced delivery of therapeutic molecules to cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4814798B1 (de) * 1968-12-26 1973-05-10
DE2455623C3 (de) * 1974-11-23 1981-04-23 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von N-Acylaminocarbonsäurepoyläthylenglykolestern
JPH0816066B2 (ja) * 1986-07-18 1996-02-21 エーザイ株式会社 持続性薬効製剤
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
FR2658521B1 (fr) * 1990-02-19 1994-01-21 Serbioo Bipeptides symetriques comportant un reste polyalkyleneglycol, procede de preparation et utilisation dans le dosage des proteases.
JP2604268B2 (ja) 1990-04-09 1997-04-30 富士写真フイルム株式会社 ペプチド誘導体両親媒性化合物、その中間体、ペプチド誘導体両親媒性化合物を用いたリポソームおよび薄膜
US5372807A (en) * 1990-05-14 1994-12-13 University Of Medicine And Dentistry Of New Jersey Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use
US5229366A (en) 1990-10-23 1993-07-20 Fuji Photo Film Co., Ltd. Peptide-containing polyethylene glycol derivatives and application thereof
JPH04208296A (ja) * 1990-11-30 1992-07-29 Fuji Photo Film Co Ltd ペプチド誘導体
US5652274A (en) * 1991-03-01 1997-07-29 Martin; Alain Therapeutic-wound healing compositions and methods for preparing and using same
JPH04297494A (ja) * 1991-03-26 1992-10-21 Fuji Photo Film Co Ltd ペプチド誘導体とその用途
GB9120653D0 (en) 1991-09-27 1991-11-06 Procter & Gamble Dispensing agent
US5580563A (en) 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
DE69730218D1 (de) 1996-04-11 2004-09-16 Univ British Columbia Fusogene liposomen

Also Published As

Publication number Publication date
US6417326B1 (en) 2002-07-09
US7205273B2 (en) 2007-04-17
US20030125517A1 (en) 2003-07-03
CA2252055C (en) 2007-01-16
WO1997038010A3 (en) 1998-02-05
CA2252055A1 (en) 1997-10-16
WO1997038010A2 (en) 1997-10-16
AU2284697A (en) 1997-10-29
EP0910576A2 (de) 1999-04-28
DE69730218D1 (de) 2004-09-16
EP0910576B1 (de) 2004-08-11

Similar Documents

Publication Publication Date Title
DE69730218D1 (de) Fusogene liposomen
DE69832293D1 (de) Zubereitungen zur abgabe von negativ geladenen molekülen
FI950887L (fi) MAGE-3-geenistä peräisin oleva ja HLA-A1-proteiinin tarjoama eristetty nonapeptidi ja sen käytöt
DE69534778D1 (en) Cathepsin-02-protease
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
NO993257L (no) N-acylfosfatidyletanolaminformidlet liposomal legemiddelavlevering
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
DE69823046D1 (de) Praktische in vitro sialylierung von rekombinanten glykpproteinen
NO20020348L (no) Peptid acceptor ligeringsmetoder
ATE398630T1 (de) Zyklische conotoxin-peptide
ATE459340T1 (de) Zielgerichtete liposomen zur verabreichung von genen
MX9806041A (es) Proteina purificada sr-p70.
ATE345778T1 (de) (ester)-lysolecithine in liposomen
MY138219A (en) Biologically active peptides
ATE214708T1 (de) Kationische mittel zur transfektion von nukleinsäuren
TR200001055T2 (tr) Yeni metilenbifosfonik asit türevleri
DE69733948D1 (de) In vivo herstellung von replicativen molekülen
AU5163598A (en) Novel hepatitis b inhibitors
WO2002044195A3 (en) Method for base sequencing and biologically active nucleic acids
ATE299704T1 (de) Warmgeformte feste arzneizusammensetzung zur gesteuerten wirkstoffabgabe von perindopril
ATE359764T1 (de) Durch liposome vermittelte dna verabreichung
GR980100008A (el) Πολυδιαστατο μοριακο ενδοστηριγμα στην υλη
ZA9811804B (en) 11ß-halogen-7Ó-substituted estratrienes, process for the production of pharmaceutical preparations that contain these 11ß-halogen-7Ó-substituted estratrienes as well as their use for the production of pharmaceutical agents.
MX9708111A (es) Lipidos cationicos para terapia genica.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties